Gastric cancer prevention and screening during pancreatic cancer screening in high-risk individuals: an opportunity not to be missed
Pancreatic adenocarcinoma is associated with a hereditary component in approximately 5% to 10% of cases. Individuals with family history of pancreatic cancer carrying pathogenic or likely pathogenic mutations in genes such as BRCA1, BRCA2, CDKN2A, mismatch repair (MMR) genes associated with Lynch syndrome (MSH2, MLH1, MSH6, EPCAM; excluding PMS2), ATM, PALB2, STK11, and TP53 have a higher incidence of disease compared with those with family history of pancreatic cancer alone.1-4 Similarly, a greater predisposition of developing disease is reported for individuals with hereditary pancreatitis or Ashkenazi Jewish ancestry, the latter in part attributable to a higher carrier frequency of founder BRCA1/BRCA2 mutations.
